Home » Newsletters » BioWorld Science

BioWorld Science

April 29, 2019

View Archived Issues

Clotbuster's clot-busting may be beside the point

Preclinical results of a systemic mRNA therapy for Fabry disease

Discovery of novel selective hematopoietic prostaglandin D synthase inhibitors

Takeda's TAK-981 inhibits SUMOylation in vivo, heads to phase I

Sun Yat-sen University describes mesenchymal stem cells overexpressing CCR2

AEBi Accelerated Evolution Biotechnologies presents cytotoxic peptides

New NLRP3 inflammasome inhibitors patented by Inflazome

Theralase initiates phase II study of TLD-1433 in nonmuscle-invasive bladder cancer

Prevail Therapeutics describes glucocerebrosidase constructs

New regenerative therapy developed for Strep pneumonia

Rapid diagnosis of rare diseases

KIAA0125 found to be a diagnostic marker in ameloblastoma

Preclinical characterization of a novel oHSV-expressing bispecific antibody, ONCR-148

ARHGEF2 as a novel prognosis marker in pancreatic cancer

Novel animal model of advanced NASH mimics main characteristics of human disease

FDA approves intravenous Benlysta for pediatric SLE

FDA approves Praluent to reduce risk of heart attack, stroke and unstable angina

First-in-human trial scheduled for TGF-beta receptor type-1 inhibitor GFH-018

Guangdong Zhongsheng Pharmaceutical completes phase I study of ZSP-1273

Novo Nordisk reports phase III results with Victoza in pediatric type 2 diabetes

AstraZeneca and Ionis Pharmaceuticals collaborate on antisense oligonucleotide targeting FOXP3

4D Pharma offers update on development of MRx-0518

European Commission approves Zynquista for type 1 diabetes

Conditional marketing authorization granted in E.U. for Ondexxya to reverse factor Xa inhibitors

Maruishi reports results from Japanese phase III study of Traumakine in ARDS

ObsEva reports follow-up data from phase III IMPLANT2 study of nolasiban

Omeicos doses first patient in phase II study of OMT-28 for atrial fibrillation

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...